Outcome of metastasis directed therapy
Men with histologically confirmed prostate cancer
Men who have undergone radical prostatectomy (RP), with or without extended pelvic lymph node dissection (ePLND)
Men with pNx or pN0 status in the ePLND specimen
Biochemical recurrence after RP (PSA > 0.2 ng/mL on two occasions)
Previous salvage radiotherapy to the prostate bed
Men with lymph node metastases outside the pelvis (M1a)
Men with osseous metastases (M1b) or visceral metastases (M1c)
Men with lymphogenic metastases and a local recurrence
Men with histologically confirmed prostate cancer who have undergone radical prostatectomy, have experienced biochemical (PSA) recurrence, and have lymphogenic metastases in the pelvic region on PSMA PET/CT.
Cohort
Prospective
Not listed
The primary endpoint is the number of patients (and percentage of the total) with metastases on PSMA PET/CT two years after study initiation.
Click on the lead sponsor to view all of their trials.
Amsterdam UMC, location VUmc
Lead sponsor
Accord Healthcare, Inc.
Collaborator
This trial is not recruiting at the moment. You can still explore other options:
